

Kelley, Stephen P., Walsh, Jacqueline, Kelly, Mark C., Muhdar, Simerjyot, Adel-Aziz, Mohammed, Barrett, Iain D. and Wildman, Scott S.P. (2014) *Inhibition of native 5-HT₃ receptor-evoked contractions in guinea pig and mouse ileum by antimalarial drugs*. European Journal of Pharmacology, 738 . pp. 186-191. ISSN 0014-2999.

Downloaded from

<https://kar.kent.ac.uk/53095/> The University of Kent's Academic Repository KAR

The version of record is available from

<https://doi.org/10.1016/j.ejphar.2014.05.043>

This document version

UNSPECIFIED

DOI for this version

Licence for this version

CC BY-NC-ND (Attribution-NonCommercial-NoDerivatives)

Additional information

Versions of research works

Versions of Record

If this version is the version of record, it is the same as the published version available on the publisher's web site. Cite as the published version.

Author Accepted Manuscripts

If this document is identified as the Author Accepted Manuscript it is the version after peer review but before type setting, copy editing or publisher branding. Cite as Surname, Initial. (Year) 'Title of article'. To be published in *Title of Journal*, Volume and issue numbers [peer-reviewed accepted version]. Available at: DOI or URL (Accessed: date).

Enquiries

If you have questions about this document contact ResearchSupport@kent.ac.uk. Please include the URL of the record in KAR. If you believe that your, or a third party's rights have been compromised through this document please see our [Take Down policy](https://www.kent.ac.uk/guides/kar-the-kent-academic-repository#policies) (available from <https://www.kent.ac.uk/guides/kar-the-kent-academic-repository#policies>).



ELSEVIER

Contents lists available at ScienceDirect

European Journal of Pharmacology

journal homepage: www.elsevier.com/locate/ejphar

Pulmonary, gastrointestinal and urogenital pharmacology

Inhibition of native 5-HT₃ receptor-evoked contractions in guinea pig and mouse ileum by antimalarial drugsStephen P. Kelley*, Jacqueline Walsh, Mark C. Kelly, Simerjyot Muhdar, Mohammed Adel-Aziz, Iain D. Barrett¹, Scott S. Wildman

Medway School of Pharmacy, Universities of Kent and Greenwich Chatham Maritime, UK

ARTICLE INFO

Article history:

Received 5 December 2013

Received in revised form

22 May 2014

Accepted 23 May 2014

Available online 2 June 2014

Keywords:

5-HT

Quinine

Chloroquine

Mefloquine

Gastrointestinal

Contractions

ABSTRACT

Quinine, chloroquine and mefloquine are commonly used to treat malaria, however, with associated gastrointestinal (GI) side-effects. These drugs act as antagonists at recombinant 5-HT₃ receptors and modulate gut peristalsis. These gastrointestinal side effects may be the result of antagonism at intestinal 5-HT₃ receptors. Ileum from male C57BL/6 mice and guinea pigs was mounted longitudinally in organ baths. The concentration–response curves for 5-HT and the selective 5-HT₃ agonist 2-Me-5-HT were obtained with 5-HT (pEC₅₀ = 7.57 ± 0.33, 12) more potent (*P* = 0.004) than 2-Me-5-HT (pEC₅₀ = 5.45 ± 0.58, *n* = 5) in mouse ileum. There was no difference in potency of 5-HT (pEC₅₀ = 5.42 ± 0.15, *n* = 8) and 2-Me-5-HT (pEC₅₀ = 5.01 ± 0.55, *n* = 11) in guinea pig ileum (*P* > 0.05). Quinine, chloroquine or mefloquine was applied for 10 min and inhibitions prior to submaximal agonist application. In mouse ileum, quinine, chloroquine and mefloquine antagonised 5-HT-induced contractions (pIC₅₀ = 4.9 ± 0.17, *n* = 7; 4.76 ± 0.14, *n* = 5; 6.21 ± 0.2, *n* = 4, correspondingly) with mefloquine most potent (*P* < 0.05). Quinine, chloroquine and mefloquine antagonised 2-me-5-HT-induced contractions (pIC₅₀ = 6.35 ± 0.11, *n* = 8; 4.64 ± 0.2, *n* = 7; 5.11 ± 0.22, *n* = 6, correspondingly) with quinine most potent (*P* < 0.05). In guinea-pig ileum, quinine, chloroquine and mefloquine antagonised 5-HT-induced contractions (pIC₅₀ = 5.02 ± 0.15, *n* = 6; 4.54 ± 0.1, *n* = 7; 5.32 ± 0.13, *n* = 5) and 2-me-5-HT-induced contractions (pIC₅₀ = 4.62 ± 0.25, *n* = 5; 4.56 ± 0.14, *n* = 6; 5.67 ± 0.12, *n* = 4) with chloroquine least potent against 5-HT and mefloquine most potent against 2-me-5-HT (*P* < 0.05). These results support previous studies identifying anti-malarial drugs as antagonists at recombinant 5-HT₃ receptors and may also demonstrate the ability of these drugs to influence native 5-HT₃ receptor-evoked contractile responses which may account for their associated GI side-effects.

© 2014 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/3.0/>).

1. Introduction

Enterochromaffin (EC) cells, within the epithelial layer of the gastrointestinal tract, release 5-HT and account for 90% of the body's store of 5-HT (Bueno, 2005). A variety of 5-HT receptors located on intestinal cells modulate peristalsis (Tuladhar et al., 2003, 1997, 2000) and secretions (Turvill et al., 2000). These include 5-HT_{1A}, 5-HT₃, 5-HT₄, and 5-HT₇ receptors (Hoyer et al., 2002). 5-HT₃ receptors play an important role in the excitability of the enteric nervous system, contributing to fast excitatory post-synaptic potentials in neurones of the myenteric and submucosal plexuses (Galligan, 2002, 2000; Michel et al., 2005). 5-HT₃ receptors are distributed throughout the human, guinea pig, rat and

mouse intestine (Butler et al., 1990; Champaneria et al., 1992; Chetty et al., 2006, 2008; Gaddum and Picarelli, 1957; Kapeller et al., 2011), and play a pivotal role in modulating intestinal motility (Chetty et al., 2006; Liu et al., 2011; Mayer et al., 2006). Additionally, 5-HT₃ receptor antagonists such as ramosetron have been indicated for diarrhoea-predominant irritable bowel syndrome by blocking intestinal 5-HT₃ receptors (Lee et al., 2011).

The principal side effects of quinine, chloroquine and mefloquine include gastrointestinal disturbances such as nausea, vomiting, diarrhoea and constipation (Barrett et al., 1996; Fogh et al., 1988; White, 1992). This may be partially due to an interaction with receptors or ion channels expressed within the gut and the enteric nervous system. Quinine is known to block voltage-gated K⁺ channels (Schmalz et al., 1998) and chloroquine may indirectly modulate large Ca²⁺-activated K⁺ channels (BKCa) in the ileum (Jing et al., 2013). Quinine, chloroquine, and mefloquine have also been shown to act as antagonists at human and mouse recombinant 5-HT_{3A} homo-oligomeric receptors expressed in *Xenopus* oocytes (Thompson et al., 2007; Thompson and Lummis, 2008).

* Correspondence to: Medway School of Pharmacy, Anson Building, Central Avenue Universities of Kent and Greenwich Chatham Maritime, UK.
Tel.: +44 1634 202 957; fax: +44 1634 883 927.

E-mail address: s.p.kelley@kent.ac.uk (S.P. Kelley).

¹ Albany Medical Center, 43 New Scotland Avenue, Albany, NY 12208, USA.

Additionally, quinine, chloroquine and mefloquine can displace [^3H]granisteron binding to mouse recombinant 5-HT $_3$ receptors (Thompson et al., 2007) indicating that these anti-malarial drugs directly bind to the 5-HT binding site on the receptor. We hypothesise that these anti-malarial drugs, quinine, chloroquine and mefloquine will also act as antagonists at native 5-HT $_3$ receptors in the small intestine, and by doing so may significantly attenuate 5-HT $_3$ -mediated contractions. In an attempt to investigate this hypothesis, we have utilised both mouse and guinea-pig isolated ileum preparations and examined the ability of the anti-malarial compounds, quinine, chloroquine and mefloquine to antagonise 5-HT and 5-HT $_3$ mediated contractions. The rationale for using both mouse and guinea pig ileum being that the action of anti-malarial compounds at recombinant mouse 5-HT $_{3A}$ homooligomeric receptors has been evaluated previously (Thompson et al., 2007) and the guinea-pig 5-HT $_{3A}$ subunit (Lankiewicz et al., 2000) has a 85% sequence homology with its human counterpart with relatively similar agonist pharmacology to human recombinant 5-HT $_{3A}$ receptors (Belelli et al., 1995).

2. Materials and methods

2.1. Preparation of tissues

Male C57BL/6 mice (25–35 g; Charles River Laboratories, Margate, UK) were killed by cervical dislocation and the ileum was excised 2 cm before the ileo-caecal junction and placed in Tyrode's solution (in mM: NaCl 137, KCl 2.7, CaCl $_2$ 1.8, MgCl $_2$ 1.0, NaH $_2$ PO $_4$ 0.42, NaHCO $_3$ 12.0, Glucose 5.5, pH 7.4). Segments of whole ileum (3–4 cm) were then carefully mounted longitudinally in 50 ml water jacketed organ baths containing Tyrode's solution continuously aerated with 95% O $_2$ /5% CO $_2$ and kept at 35–37 °C. The ileum segments were allowed to equilibrate for 30 min whilst mechanically attached to a force transducer with a resting tension of 0.5 g. The contractile responses were recorded by the forced transducer and visualised by means of a chart recorder.

Portions of guinea pig ileum were obtained from adult male guinea pigs (200–300 g, Charles River, Laboratories, Margate, UK). The ileum was cut into 3.5–4 cm and mounted in a similar manner to that of mouse ileum. The tissues were equilibrated for 30 min followed by an initial application of acetylcholine (ACh; 1 μM) to establish the integrity of the tissue at the start of the experiment. All procedures involving animals were approved by the University of Kent Animal Welfare and Ethical Review Body in accordance with the UK Animals (Scientific Procedures) Act (1986).

2.2. Drugs

Acetylcholine, chloroquine, quinine (Sigma Aldrich, Poole, UK), 5-hydroxytryptamine hydrochloride (Tocris Bioscience, Bristol, UK), 2-methyl-5-HT (Tocris Bioscience, Bristol, UK) were dissolved in Tyrode's solution. Mefloquine (Sigma Aldrich, Poole, UK) was dissolved in 50% dimethyl sulfoxide then diluted in Tyrode's solution to a final dimethyl sulfoxide concentration of $\leq 0.3\%$. 5-HT and 2-methyl-5-HT were applied to the serosal layer of the ileum and responses recorded for 30 s which was sufficient for capturing the maximal contraction evoked from the drug. The Tyrode's solution was then flushed and the organ bath filled with fresh Tyrode's solution. The ileum was then maintained for 10 min prior to application of the next agonist concentration. For the anti-malarial (antagonist) compounds, application was also made to the serosal layer, however the ileum remained in contact with the anti-malarial compounds for 10 min. Following this 10 min interval, agonist was applied in the manner described above and the agonist evoked response recorded. The application of antagonists

was not initiated until at least two agonist baseline responses (mm) in the absence of an antagonist did not differ greater than 5%.

2.3. Analysis of results

To construct the 5-HT and 2-me-5-HT agonist concentration–response curves, individual agonist-evoked contractile response heights (mm) were normalised to the maximal contraction height for each ileum. The mean normalised responses \pm S.E.M. for each agonist concentration in a series were iteratively fitted using GraphPad Prism (version 6, Iowa, USA) to the non-linear regression equation

$$y = E_{min} + \frac{(E_{max} - E_{min})}{1 + 10^{(\log EC_{50} - L)/n_H}}$$

where E_{min} is the baseline contraction, E_{max} is the maximal agonist-evoked contraction, EC_{50} is the concentration of the agonist required to produce 50% of the maximal contraction, L is the log of the agonist concentration and n_H is the Hill slope. Agonist potency was expressed as EC_{50} and pEC_{50} is the negative log of the EC_{50} .

For antagonist experiments, baseline agonist response heights (mm) were measured and antagonist effects were measured as a % of the mean baseline agonist response for each ileum preparation. The relationships between increasing antimalarial (antagonist) concentration and % inhibition of agonist concentration-evoked contractions were iteratively fitted using GraphPad Prism (version 6, Iowa, USA) to the non-linear regression equation

$$y = \frac{100}{1 + 10^{(\log IC_{50} - L)/n_H}}$$

where IC_{50} is the concentration of the antagonist required to reduce to 50% of the agonist contraction, L is the log of the antagonist concentration and n_H is the Hill slope. Agonist potency was expressed as IC_{50} and pIC_{50} is the negative log of the IC_{50} .

5-HT and 2-me-5-HT pEC_{50} s were compared independently for mouse and guinea pig by a Student's t -test, whilst pIC_{50} s for each antagonist against 5-HT and 2-me-5-HT were compared by a oneway analysis of variance (ANOVA) followed by post-hoc analysis (Tukey's t). Statistical significance was defined as $P < 0.05$.

3. Results

3.1. Mouse tissue

Both 5-HT and 2-methyl-5-HT were able to evoke concentration-dependent contractions in mouse ileum tissue 5-HT which was significantly more potent in its ability to induce contraction of the ileum than 2-methyl-5-HT (Fig. 1). Potency (expressed as pEC_{50}) for 5-HT was 7.57 ± 0.33 ($n = 12$), whilst potency for 2-methyl-5-HT was 5.45 ± 0.58 ($n = 5$) (Table 1), which was significantly greater than potency for 5-HT when compared to the selective 5-HT $_3$ agonist (Student's t -test, $t = 3.36$, $df = 15$, $P = 0.004$). With increasing concentrations, quinine was able to successfully antagonise 5-HT-induced (25 nM) contractions in mouse ileum ($pIC_{50} = 4.9 \pm 0.17$, $n = 7$, Fig. 2A) with complete block at 300 μM . Chloroquine also antagonised 5-HT induced contractions ($pIC_{50} = 4.76 \pm 0.14$, $n = 5$, Fig. 2B) as did mefloquine ($pIC_{50} = 6.21 \pm 0.2$, $n = 4$, Fig. 2C) (Table 2). A one-way analysis of variance revealed a statistically significant difference in the potency of the antimalarials to act as antagonists of the 5-HT mediated contractions [$F(2, 13) = 17.90$, $P < 0.001$] with mefloquine acting as the most potent antagonist of 5-HT mediated contractions (Tukey's t , $P < 0.05$). A 10 min wash was sufficient to reinstate




Fig. 1. (A) 5-HT (●) and 2-me-5-HT (○) induced contractions in mouse ileum. 5-HT ($pEC_{50}=7.57 \pm 0.33$, $n=12$) was more potent (Student's *t*-test, $t=3.36$, $df=15$, $P < 0.01$) than 2-Me-5-HT ($pEC_{50}=5.45 \pm 0.58$, $n=5$). (B) 5-HT and 2-me-5-HT induced contractions in the guinea-pig ileum. Concentration-dependent contractions produced by 5-HT ($pEC_{50}=5.42 \pm 0.15$, $n=8$) and the selective 5-HT₃ agonist 2-Me-5-HT (5.01 ± 0.55 , $n=11$) were not significantly different (Student's *t*-test, $t=0.619$, $df=17$, $P=0.544$) in guinea pig ileum. Results are expressed as mean \pm S.E.M.




Fig. 2. Quinine (●), chloroquine (○) and mefloquine (□) block 5-HT-induced contractions in isolated mouse ileum. Increasing concentrations of quinine ($pIC_{50}=4.9 \pm 0.17$, $n=7$), chloroquine ($pIC_{50}=4.76 \pm 0.14$, $n=5$) and mefloquine ($pIC_{50}=6.21 \pm 0.2$, $n=4$) were able to antagonise 5-HT induced contractions in mouse ileum, with mefloquine significantly more potent (Tukey's *t*, $P < 0.05$). Results are expressed as mean \pm S.E.M.

5-HT-evoked contractions following the highest concentration of either quinine or chloroquine, but not mefloquine.

Quinine ($pIC_{50}=6.35 \pm 0.11$, $n=8$), chloroquine ($pIC_{50}=4.64 \pm 0.2$, $n=7$), and mefloquine ($pIC_{50}=5.11 \pm 0.22$, $n=6$) also successfully antagonised contractions evoked by the selective 5-HT₃ antagonist, 2-methyl-5-HT (10 μ M) in mouse ileum (Fig. 3). Mefloquine was also able to successfully antagonise 2-methyl-5-HT-induced contractions with complete block at 100–300 μ M. A one-way analysis of variance revealed a statistically significant difference in the potency of the antimalarials to act as antagonists of the 5-HT₃ mediated contractions [$F(2, 18)=28.82$, $P < 0.0001$] with quinine acting as the most potent antagonist of 5-HT₃ mediated contractions (Tukey's *t*, $P < 0.05$).

3.2. Guinea-pig tissue

5-HT (from 10 nM to 100 μ M) and the selective 5-HT₃ agonist 2-methyl-5-HT (from 10 nM to 30 μ M) produced




Fig. 3. Quinine (●), chloroquine (○) and mefloquine (□) block 2-me-5-HT-induced contractions in isolated mouse ileum. Increasing concentrations of quinine ($pIC_{50}=6.35 \pm 0.11$, $n=8$), chloroquine ($pIC_{50}=4.64 \pm 0.2$, $n=7$) and mefloquine ($pIC_{50}=5.11 \pm 0.22$, $n=3$) were able to antagonise 2-me-5-HT induced contractions in mouse ileum, with quinine significantly more potent (Tukey's *t*, $P < 0.05$). Results are expressed as mean \pm S.E.M.

concentration-dependent contractions in isolated guinea pig ileum. Potency (expressed as pEC_{50}) for 5-HT was 5.42 ± 0.15 , whilst potency for 2-methyl-5-HT was 5.01 ± 0.55 with no statistical significant difference in potency between the two agonists (Student's *t*-test, $t=0.619$, $df=17$, $P=0.544$, Fig. 4) (Table 1). Increasing concentrations of quinine and chloroquine were able to antagonise submaximal 5-HT-induced contractions ($pIC_{50}=5.02 \pm 0.15$, $n=6$ and $pIC_{50}=4.54 \pm 0.1$, $n=7$, correspondingly) (Fig. 5A and B). Following a 10 min wash, 5-HT-evoked contractions were reinstated. In a similar manner, increasing concentrations of mefloquine also antagonised submaximal 5-HT contractions ($pIC_{50}=5.32 \pm 0.13$, $n=5$, respectively, Fig. 5C) (Table 3), however, 5-HT-evoked contractions could not be sufficiently restored in ileum treated with the maximal concentration of mefloquine (300 μ M) following three successive washes (i.e., > 5 min). A one-way analysis of variance revealed a statistically significant difference in antagonist potency across the three anti-malarial compounds [$F(2, 14)=8.874$, $P < 0.01$] with chloroquine least potent in inhibiting 5-HT-induced contractions in the




Fig. 4. Quinine (●), chloroquine (○) and mefloquine (□) block 5-HT-induced contractions in isolated guinea-pig ileum. Increasing concentrations of quinine ($pIC_{50}=5.02 \pm 0.15$, $n=6$), chloroquine ($pIC_{50}=4.54 \pm 0.1$, $n=7$) and mefloquine ($pIC_{50}=5.32 \pm 0.13$, $n=6$) were able to antagonise 5-HT induced contractions in the guinea pig ileum with complete block at 100 μ M and 300 μ M applications for quinine and mefloquine. Results are expressed as mean \pm S.E.M.




Fig. 5. Quinine (●), chloroquine (○) and mefloquine (□) block 2-me-5-HT-induced contractions in isolated guinea-pig ileum. Increasing concentrations of quinine ($pIC_{50}=4.62 \pm 0.25$, $n=5$), chloroquine ($pIC_{50}=4.56 \pm 0.14$, $n=6$) and mefloquine ($pIC_{50}=5.67 \pm 0.12$, $n=4$) were able to antagonise 2-me-5-HT induced contractions in the guinea pig ileum. Results are expressed as mean \pm S.E.M.

guinea pig ileum (Tukey's t , $P < 0.05$). In addition, quinine ($pIC_{50}=4.62 \pm 0.25$, $n=5$), chloroquine ($pIC_{50}=4.46 \pm 0.14$, $n=6$) and mefloquine ($pIC_{50}=5.67 \pm 0.12$, $n=4$) were able to block selective 5-HT₃ receptor mediated contractions by antagonising submaximal 2-methyl-5-HT-evoked responses (10 μ M) in a concentration dependent manner (Fig. 5). All but mefloquine were reversible within 10 min of wash. A one-way analysis of variance revealed a statistically significant difference in antagonist potency [$F(2, 12)=10.51$, $P < 0.01$] with mefloquine acting as the most potent antagonist of 5-HT₃ mediated contractions (Tukey's t , $P < 0.05$).

4. Discussion

The main findings of the current investigation are that the antimalarial compounds quinine, chloroquine and mefloquine antagonise 5-HT-evoked contractions of both mouse and guinea-

pig ileum. These drugs also antagonise 5-HT₃ receptor mediated contractions. The ability of these drugs to significantly influence the activity of key intestinal modulators, such as 5-HT, may underlie or partially account for their associated GI side effects of these drugs.

5-HT and the selective 5-HT₃ receptor agonist 2-me-5-HT produced concentration-dependent contractions in mouse and guinea-pig ileal tissue. The potency of 5-HT to produce contractions in guinea pig ileum tissue (pEC_{50} : 5.42) is very similar to previous studies which reported potencies (pEC_{50}) obtained in the presence of methysergide (e.g., 5.32, 5.38) (Butler et al., 1990; Eglen et al., 1990). The potency of the selective 5-HT₃ agonist, 2-me-5-HT (pEC_{50} : 5.01), was also very similar to previous reports (e.g., 5.4–4.91) (Butler et al., 1990, 1988; Eglen et al., 1990) adding validity to our investigation. Interestingly, 5-HT was significantly more potent as an agonist than 2-me-5-HT in producing contractile responses in mouse ileum, suggesting the possibility that a variety of 5-HT receptor subtypes may be responsible for 5-HT-evoked contraction in the mouse ileum. This is consistent with previous studies which report a greater potency for 5-HT in the mouse ileum compared to 5-HT application with 5-HT_{1,2,4,5,6,7} antagonism and 5-HT potency compared to 2-me-5-HT (Chetty et al., 2006).

The antimalarial compounds also blocked contractions evoked by 5-HT and 2-me-5-HT in mouse ileum. Interestingly, mefloquine was significantly more potent in antagonising 5-HT mediated contractions than either chloroquine or mefloquine. This pattern of antagonism is very similar to previous reports which found that mefloquine was significantly more potent in antagonising 5-HT-induced current responses in mouse recombinant 5-HT_{3A} homooligomeric receptors (Thompson et al., 2007). However, when looking at the antagonism of 2-me-5-HT mediated contractions, we found that quinine was a significantly more potent antagonist. This difference may be due to expression native 5-HT_{3AB} heterooligomeric receptor in the mouse gut (Matsumoto et al., 2013) which may be more sensitive to quinine antagonism than homooligomeric 5-HT_{3A} receptors, although no studies of recombinant mouse 5-HT_{3AB} hetero-oligomers have been completed to date. What also must be considered is that the contractions would be mediated by native receptors which may possess different regulatory sites compared to recombinant receptors, as well as being modulated by different cellular machinery compared to expression systems such as *Xenopus oocytes*.

The antimalarial compounds quinine, chloroquine and mefloquine were also able to antagonise both 5-HT and selective 5-HT₃ receptor evoked contractions in guinea pig ileal tissue. Interestingly, the antagonist action of the antimalarial compounds on native receptors expressed in tissue is very similar to previous reports of antagonist action of antimalarial compounds on recombinant receptors. Thompson et al. (2007, 2008) expressed human and mouse recombinant 5-HT₃ receptors in *Xenopus oocytes* and measured 5-HT₃ receptor-mediated inward current responses via two-electrode voltage clamping. As with the current study, both quinine and mefloquine antagonised agonist induced responses with complete block at 100–300 μ M, remarkably similar to the present results from native receptors expressed in guinea-pig tissue. The rank order of antagonist potency of 5-HT₃ receptor mediated contractions in guinea pig ileum, with mefloquine significantly more potent than quinine or chloroquine, was extremely similar to the antimalarial antagonism of current responses mediated by recombinant human 5-HT_{3AB} hetero-oligomers reported by Thompson and Lummis (2008). Based on previous studies, it is likely that the native receptors expressed in the guinea pig ileum are hetero-oligomeric receptors, and the biophysical profile of native 5-HT₃ receptors is similar to that of human 5-HT_{3AB} hetero-oligomers (Zhou and Galligan, 1999). This may explain the similar antagonist profile observed in this study.

It was noted that for guinea-pig and mouse ileum experiments, the antimalarial compounds were able to block contractions induced by the non-selective agonist 5-HT. As there are other 5-HT receptors expressed within the intestine (e.g., 5-HT_{1A}, 5-HT₄ and 5-HT₇) and these receptors may also induce or influence contractile responses, it raises the question as to whether quinine and mefloquine also have affinity for other 5-HT receptors in addition to 5-HT₃. Receptor binding experiments and subsequent docking studies conducted by Thompson et al. (2007) indicated that the antimalarial compounds quinine and chloroquine will most likely dock at the 5-HT binding site on the 5-HT₃ receptor. This may be due to the molecular similarity with these compounds and 5-HT. It is plausible that these antimalarial compounds may also bind to the 5-HT docking site at other 5-HT receptors thus potentially act as antagonists at other 5-HT receptors. This may in part explain the complete block of 5-HT induced contractions following pre-application of quinine.

Other possible factors influencing the results may be downstream receptor interaction and/or channel blockade by the antimalarial drugs. It is known that 5-HT₃ receptors can be expressed presynaptically on parasympathetic and sympathetic afferents to the gut causing release of ACh (Fox and Morton, 1990), which in turn elicits contractions of longitudinal muscle via activation of muscarinic ACh receptors. As quinine is known to act as a blocker of voltage-activated currents and muscarinic activated potassium channels (Dresviannikov et al., 2006), it is plausible that the effects observed may have been influenced in part by a blockade of these channels by quinine. Mefloquine is also known to block K⁺ channels. However it would be anticipated that a blockade of K⁺ channels would result in excitation, rather than an inhibition of contractile responses. It was noted during the experiments that following the initial application of quinine at 100–300 nM, there was a clear contraction with no responses at higher doses (data not shown). These observations would be consistent with potassium channel blockade leading towards excitation and contractile responses rather than a straightforward inhibition of the contractions. It is not clear that the results can be explained as simply a downstream blockade of muscarinic receptor activated cation channels. Both quinine and mefloquine completely antagonised 5-HT induced contractions, which may indicate an antagonism at 5-HT₂ receptors, as well as 5-HT₃ and 5-HT₄ receptors. It is known that 5-HT₂ induced contractions are not influenced or dependent upon cholinergic receptor activation or inhibition. Therefore this would imply that the effects of quinine and mefloquine observed upon 5-HT induced contractions cannot be due exclusively to an interaction at muscarinic receptor activated channels.

It should be noted that this study has focused exclusively on isolated intestinal tissue preparations. The antimalarial drugs may have direct central effects. Ondansetron, a selective 5-HT₃ antagonist and antiemetic drug, produces its antiemetic effect by blocking peripheral 5-HT₃ receptors on vagal afferents and brain 5-HT₃ receptors expressed in the medullary chemoreceptor zone (Gan, 2005). It is plausible that the antimalarial drugs would act at the same central 5-HT₃ receptors producing an antiemetic effect. Mefloquine has the ability to cross the blood brain barrier (Baudry et al., 1997). However, quinine and chloroquine cannot easily cross the blood brain barrier (Hagihara et al., 2000; Silamut et al., 1985) and this would be expected to impede any possible antiemetic effects by these drugs by acting at central 5-HT₃ receptors.

In conclusion, the present findings present an inhibition of both 5-HT and 5-HT₃ receptor-mediated contractions in both guinea-pig and mouse ileum tissue by the antimalarial drugs quinine, chloroquine and mefloquine. These results strongly suggest that these antimalarial drugs will directly interact and influence physiological function in the gut and may inhibit or

Table 1
5-HT and 2-me-5-HT-evoked contraction in isolated mouse and guinea pig ileum.

Agonist	EC ₅₀ (μM)	pEC ₅₀ (± S.E.M.)	n
Mouse ileum tissue			
5-HT	27.12	7.57 (± 0.33)	12
2-me-5-HT	3.5	5.45 (± 0.58)	5
Guinea pig ileum tissue			
5-HT	3.8	5.42 (± 0.15)	8
2-me-5-HT	9.7	5.01 (± 0.55)	11

Table 2
Inhibition of agonist evoked contractions in isolated mouse ileum by antimalarial compounds.

Antimalarial	IC ₅₀ (μM)	pIC ₅₀ (± S.E.M.)	n
Inhibition of 5-HT-evoked contractions			
Quinine	12.5	4.9 (± 0.17)	7
Chloroquine	17.6	4.76 (± 0.14)	5
Mefloquine	0.62	6.21 (± 0.2)	4
Inhibition of 2-me-5-HT-evoked contractions			
Quinine	0.44	6.35 (± 0.11)	8
Chloroquine	22.9	4.64 (± 0.2)	7
Mefloquine	7.85	5.11 (± 0.22)	6

Table 3
Inhibition of agonist evoked contractions in isolated guinea pig ileum by antimalarial compounds.

Antimalarial	IC ₅₀ (μM)	pIC ₅₀ (± S.E.M.)	n
Inhibition of 5-HT-evoked contractions			
Quinine	9.46	5.02 (± 0.15)	6
Chloroquine	28.71	4.54 (± 0.1)	7
Mefloquine	4.78	5.32 (± 0.13)	5
Inhibition of 2-me-5-HT-evoked contractions			
Quinine	24	4.62 (± 0.25)	5
Chloroquine	27.48	4.56 (± 0.14)	6
Mefloquine	2.15	5.67 (± 0.12)	4

disrupt normal contraction reflex responses at high concentrations. It is possible that the GI side-effects reported for these compounds may partially be the result of antagonist action at 5-HT₃ receptors.

Author contribution

SPK conceived the principal question and designed the experiments.

SPK and SSW wrote the manuscript.

SPK, JW, MCK, SM, MAA, & IDB conducted the experiments.

Acknowledgements

The authors would like to thank Dr. Andrew Thompson and Dr. Sarah Lummis, Cambridge University, for an initial donation of the anti-malarial drugs and comments on an earlier version of the manuscript.

References

- Barrett, P.J., Emmins, P.D., Clarke, P.D., Bradley, D.J., 1996. Comparison of adverse events associated with use of mefloquine and combination of chloroquine and proguanil as antimalarial prophylaxis: postal and telephone survey of travellers. *Br. Med. J.* 313 (7056), 525–528.
- Baudry, S., Pham, Y.T., Baune, B., Vidrequin, S., Crevoisier, C., Gimenez, F., et al., 1997. Stereoselective passage of mefloquine through the blood–brain barrier in the rat. *J. Pharm. Pharmacol.* 49 (11), 1086–1090.
- Belelli, D., Balcarek, J.M., Hope, A.G., Peters, J.A., Lambert, J.J., Blackburn, T.P., 1995. Cloning and functional expression of a human 5-hydroxytryptamine type 3A5 receptor subunit. *Mol. Pharmacol.* 48 (6), 1054–1062.
- Bueno, L., 2005. Gastrointestinal pharmacology: irritable bowel syndrome. *Curr. Opin. Pharmacol.* 5 (6), 583–588.
- Butler, A., Elswood, C.J., Burrige, J., Ireland, S.J., Bunce, K.T., Kilpatrick, G.J., et al., 1990. The pharmacological characterization of 5-HT₃ receptors in three isolated preparations derived from guinea-pig tissues. *Br. J. Pharmacol.* 101 (3), 591–598.
- Butler, A., Hill, J.M., Ireland, S.J., Jordan, C.C., Tyers, M.B., 1988. Pharmacological properties of GR38032F, a novel antagonist at 5-HT₃ receptors. *Br. J. Pharmacol.* 94 (2), 397–412.
- Champaneria, S., Costall, B., Naylor, R.J., Robertson, D.W., 1992. Identification and distribution of 5-HT₃ recognition sites in the rat gastrointestinal tract. *Br. J. Pharmacol.* 106 (3), 693–696.
- Chetty, N., Irving, H.R., Coupar, I.M., 2006. Activation of 5-HT₃ receptors in the rat and mouse intestinal tract: a comparative study. *Br. J. Pharmacol.* 148 (7), 1012–1021.
- Chetty, N., Irving, H.R., Coupar, I.M., 2008. Effects of the novel 5-HT₃ agonist MKC-733 on the rat, mouse and guinea pig digestive tract. *Pharmacology* 81 (2), 104–109.
- Dresviannikov, A.V., Bolton, T.B., Zholos, A.V., 2006. Muscarinic receptor-activated cationic channels in murine ileal myocytes. *Br. J. Pharmacol.* 149 (2), 179–187.
- Eglen, R.M., Swank, S.R., Walsh, L.K., Whiting, R.L., 1990. Characterization of 5-HT₃ and 'atypical' 5-HT receptors mediating guinea-pig ileal contractions in vitro. *Br. J. Pharmacol.* 101 (3), 513–520.
- Fogh, S., Schapira, A., Bygbjerg, I.C., Jepsen, S., Mordhorst, C.H., Kuijlen, K., et al., 1988. Malaria chemoprophylaxis in travellers to east Africa: a comparative prospective study of chloroquine plus proguanil with chloroquine plus sulfadoxine-pyrimethamine. *Br. Med. J. (Clin. Res. Ed.)* 296 (6625), 820–822.
- Fox, A., Morton, I.K., 1990. An examination of the 5-HT₃ receptor mediating contraction and evoked [3H]-acetylcholine release in the guinea-pig ileum. *Br. J. Pharmacol.* 101 (3), 553–558.
- Gaddum, J.H., Picarelli, Z.P., 1957. Two kinds of tryptamine receptor. *Br. J. Pharmacol.* 12 (3), 323–328.
- Galligan, J.J., 2002. Ligand-gated ion channels in the enteric nervous system. *Neurogastroenterol. Motil.* 14 (6), 611–623.
- Galligan, J.J., LePard, K.J., Schneider, D.A., Zhou, X., 2000. Multiple mechanisms of fast excitatory synaptic transmission in the enteric nervous system. *J. Auton. Nerv. Syst.* 81 (1–3), 97–103.
- Gan, T.J., 2005. Selective serotonin 5-HT₃ receptor antagonists for postoperative nausea and vomiting: are they all the same? *CNS Drugs* 19 (3), 225–238.
- Hagihara, N., Walbridge, S., Olson, A.W., Oldfield, E.H., Youle, R.J., 2000. Vascular protection by chloroquine during brain tumor therapy with Tf-CRM107. *Cancer Res.* 60 (2), 230–234.
- Hoyer, D., Hannon, J.P., Martin, G.R., 2002. Molecular, pharmacological and functional diversity of 5-HT receptors. *Pharmacol. Biochem. Behav.* 71 (4), 533–554.
- Jing, F., Liu, M., Yang, N., Liu, Y., Li, X., Li, J., 2013. Relaxant effect of chloroquine in rat ileum: possible involvement of nitric oxide and BKCa. *J. Pharm. Pharmacol.* 65 (6), 847–854.
- Kapeller, J., Moller, D., Lasitschka, F., Autschbach, F., Hovius, R., Rappold, G., et al., 2011. Serotonin receptor diversity in the human colon: expression of serotonin type 3 receptor subunits 5-HT_{3C}, 5-HT_{3D}, and 5-HT_{3E}. *J. Comp. Neurol.* 519 (3), 420–432.
- Lankiewicz, S., Huser, M.B., Heumann, R., Hatt, H., Gisselmann, G., 2000. Phosphorylation of the 5-hydroxytryptamine₃ (5-HT₃) receptor expressed in HEK293 cells. *Recept. Channels* 7 (1), 9–15.
- Lee, K.J., Kim, N.Y., Kwon, J.K., Huh, K.C., Lee, O.Y., Lee, J.S., et al., 2011. Efficacy of ramosetron in the treatment of male patients with irritable bowel syndrome with diarrhea: a multicenter, randomized clinical trial, compared with mebeverine. *Neurogastroenterol. Motil.* 23 (12), 1098–1104.
- Liu, H.N., Ohya, S., Nishizawa, Y., Sawamura, K., Iino, S., Syed, M.M., et al., 2011. Serotonin augments gut pacemaker activity via 5-HT₃ receptors. *PLoS One* 6 (9), e24928.
- Matsumoto, K., Nakajima, T., Sakai, H., Kato, S., Sagara, A., Arakawa, K., et al., 2013. Increased expression of 5-HT and NK receptors in 5-fluorouracil-induced mucositis in mouse jejunum. *Dig. Dis. Sci.* 58 (12), 3440–3451.
- Mayer, E.A., Tillisch, K., Bradesi, S., 2006. Review article: modulation of the brain-gut axis as a therapeutic approach in gastrointestinal disease. *Aliment. Pharmacol. Ther.* 24 (6), 919–933.
- Michel, K., Zeller, F., Langer, R., Nekarda, H., Kruger, D., Dover, T.J., et al., 2005. Serotonin excites neurons in the human submucous plexus via 5-HT₃ receptors. *Gastroenterology* 128 (5), 1317–1326.
- Schmalz, F., Kinsella, J., Koh, S.D., Vogalis, F., Schneider, A., Flynn, E.R., et al., 1998. Molecular identification of a component of delayed rectifier current in gastrointestinal smooth muscles. *Am. J. Physiol.* 274 (5 Pt 1), G901–G911.
- Silamut, K., White, N.J., Looareesuwan, S., Warrell, D.A., 1985. Binding of quinine to plasma proteins in falciparum malaria. *Am. J. Trop. Med. Hyg.* 34 (4), 681–686.
- Thompson, A.J., Lochner, M., Lummis, S.C., 2007. The antimalarial drugs quinine, chloroquine and mefloquine are antagonists at 5-HT₃ receptors. *Br. J. Pharmacol.* 151 (5), 666–677.
- Thompson, A.J., Lummis, S.C., 2008. Antimalarial drugs inhibit human 5-HT₃ and GABA(A) but not GABA(C) receptors. *Br. J. Pharmacol.* 153 (8), 1686–1696.
- Tuladhar, B.R., Ge, L., Naylor, R.J., 2003. 5-HT₇ receptors mediate the inhibitory effect of 5-HT on peristalsis in the isolated guinea-pig ileum. *Br. J. Pharmacol.* 138 (7), 1210–1214.
- Tuladhar, B.R., Kaiser, M., Naylor, R.J., 1997. Evidence for a 5-HT₃ receptor involvement in the facilitation of peristalsis on mucosal application of 5-HT in the guinea pig isolated ileum. *Br. J. Pharmacol.* 122 (6), 1174–1178.
- Tuladhar, B.R., Womack, M.D., Naylor, R.J., 2000. Pharmacological characterization of the 5-HT receptor-mediated contraction in the mouse isolated ileum. *Br. J. Pharmacol.* 131 (8), 1716–1722.
- Turvill, J.L., Connor, P., Farthing, M.J., 2000. The inhibition of cholera toxin-induced 5-HT release by the 5-HT₃ receptor antagonist, granisetron, in the rat. *Br. J. Pharmacol.* 130 (5), 1031–1036.
- White, N.J., 1992. Antimalarial pharmacokinetics and treatment regimens. *Br. J. Clin. Pharmacol.* 34 (1), 1–10.
- Zhou, X., Galligan, J.J., 1999. Synaptic activation and properties of 5-hydroxytryptamine₃ receptors in myenteric neurons of guinea pig intestine. *J. Pharmacol. Exp. Ther.* 290 (2), 803–810.